Protecting Our Forces - Institute Of Medicine; Medical Follow-Up Agency; Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance Vaccine Issues in the U S Military
45,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
23 °P sammeln
  • Broschiertes Buch

Infectious diseases continue to pose a substantial threat to the operational capacity of military forces. "Protecting Our Forces reviews the process by which the U.S. military acquires vaccines to protect its war fighters from natural infectious disease threats. The committee found that poorly aligned acquisition processes and an inadequate commitment of financial resources within the Department of Defense vaccine acquisition process--rather than uncleared scientific or technological hurdles--contribute to the unavailability of some vaccines; that could protect military personnel and,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Infectious diseases continue to pose a substantial threat to the operational capacity of military forces. "Protecting Our Forces reviews the process by which the U.S. military acquires vaccines to protect its war fighters from natural infectious disease threats. The committee found that poorly aligned acquisition processes and an inadequate commitment of financial resources within the Department of Defense vaccine acquisition process--rather than uncleared scientific or technological hurdles--contribute to the unavailability of some vaccines; that could protect military personnel and, implicitly, the welfare and security of the nation. "Protecting Our Forces outlines ways in which DoD might strengthen its acquisition process and improve vaccine availability. Recommendations, which include combining all DoD vaccine acquisition responsibilities under a single DoD authority, cover four broad aspects of the acquisition process: (1) organization, authority, and responsibility; (2) program and budget; (3) manufacturing; and (4) the regulatory status of special-use vaccines.